Biomarkers (2009) 14(8):58795.10.3109/13547500903183954 30 NeumanRBBloomHLShukrullahIDarrowLAKleinbaumDJonesDPet alOxidative stress markers are associated with persistent atrial fibrillation
Why IVF increases APD risk IVF protocols commonly require progesterone injections, suppositories, or oral formulations at doses much higher than those produced during a natural cycle Exogenous progesterone bypasses the bodys normal regulatory mechanisms, increasing the likelihood of mast cell activation and histamine release Repeated exposure during fertility treatment may unmask previously undiagnosed APD or worsen existing symptoms When progesterone desensitization is used Desensitization protocols may be recommended before or during IVF for individuals with known or suspected APD These protocols involve carefully supervised, incremental exposure to progesterone to reduce immune reactivity Desensitization is most often used when progesterone cannot be avoided, such as during luteal support or early pregnancy Role of antihistamines and corticosteroids during IVF Antihistamines (such as H1 and H2 blockers) are commonly used to blunt histamine-mediated symptoms during progesterone exposure Short-term corticosteroids may be prescribed to control severe inflammatory or allergic reactions during treatment cycles These medications do not treat the underlying hypersensitivity but can help protect patient safety and treatment continuity In some cases, clinicians may also consider antioxidant support such as NAC to help manage inflammatory stress during fertility treatment or pregnancy , though this should always be individualized
Diagnostic features: A few to numerous glandular structures diffusely scattered in the hepatic parenchyma
Hydration Support To hydrate skin, the formulation incorporates plant-derived Squalane (which makes up over 50% of the formulation), as well as Glycogen and Zizanoic Vetiver, to help restore skins hydration reservoirs
Survodutide Research# Survodutide has two published Phase 2 trials: the obesity trial (Lancet Diabetes & Endocrinology, 2024) showing 18.7% weight loss at 46 weeks, and the MASH trial (NEJM, 2024) showing 62% MASH resolution
Hao Y, Gao X
